Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.
Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.Peer-Reviewed Original ResearchICD9 codesBarcelona Clinic Liver Cancer stageOverall median survival rateInitial dosing regimensLiver Cancer stageMedian survival rateSimilar treatment durationCTP AECOG PSExtrahepatic spreadChild-TurcotteMacrovascular invasionMELD scorePrescriber specialtyReal-world practiceMedian agePharmacy recordsSorafenib exposureBCLC 0Dosing regimensLiver diseaseTumor numberPrescribing practicesHCC patientsCancer stageAssociation of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC).
Ilagan-Ying Y, Kaplan D, Taddei T, Njei B. Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2017, 35: 255-255. DOI: 10.1200/jco.2017.35.4_suppl.255.Peer-Reviewed Original ResearchHepatocellular carcinomaCause mortalityVeterans Administration Corporate Data WarehouseStage of HCCBCLC stage BBCLC stage DLiver disease severityAdvanced-stage cancerUseful prognostic markerAssociation of changesDate of deathLogistic regression analysisPotential hepatocellular carcinomaManual chart abstractionRegression analysisCorporate Data WarehouseChart abstractionBCLC 0Tumor burdenLiver diseaseTumor stagingUS veteransPrognostic markerHCC casesDiagnostic confirmation